Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 0.88 [0.81, 0.97] | | < 1 | | 0% | 5 studies (5/-) | 99.6 % | low | not evaluable | high | crucial | - |
PFS (extension) | 0.80 [0.69, 0.92] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | important | - |
progression or deaths (PFS) | 0.92 [0.64, 1.31] | | < 1 | | 93% | 4 studies (4/-) | 68.1 % | low | not evaluable | high | important | - |
DCR | 0.60 [0.39, 0.94] | | > 1 | | 0% | 1 study (1/-) | 1.3 % | NA | not evaluable | | non important | - |
DOR | 0.78 [0.63, 0.97] | | < 1 | | 0% | 1 study (1/-) | 98.6 % | NA | not evaluable | | non important | - |
events or deaths (EFS) | 0.76 [0.40, 1.44] | | < 1 | | 0% | 1 study (1/-) | 79.9 % | NA | not evaluable | | non important | - |
objective responses (ORR) | 0.85 [0.31, 2.31] | | > 1 | | 97% | 4 studies (4/-) | 37.2 % | low | not evaluable | high | non important | - |
pCR | 1.95 [1.26, 3.01] | | > 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
AE (any grade) | 1.71 [0.75, 3.93] | | < 1 | | 0% | 3 studies (3/-) | 10.2 % | low | not evaluable | high | non important | - |
AE (grade 3-4) | 1.25 [1.04, 1.51] | | < 1 | | 0% | 3 studies (3/-) | 0.9 % | low | not evaluable | high | non important | - |
AE leading to death (grade 5) | 1.71 [0.49, 5.92] | | < 1 | | 0% | 2 studies (2/-) | 20.1 % | low | not evaluable | high | non important | - |
AE leading to treatment discontinuation (any grade) | 1.66 [0.89, 3.11] | | < 1 | | 71% | 2 studies (2/-) | 5.6 % | low | not evaluable | high | non important | - |
SAE (any grade) | 1.34 [0.94, 1.90] | | < 1 | | 55% | 3 studies (3/-) | 5.1 % | low | not evaluable | high | non important | - |
STRAE (any grade) | 1.72 [1.21, 2.45] | | < 1 | | 0% | 2 studies (2/-) | 0.1 % | low | not evaluable | high | non important | - |
TRAE (any grade) | 1.54 [0.98, 2.42] | | < 1 | | 0% | 3 studies (3/-) | 3.1 % | low | not evaluable | high | non important | - |
TRAE (grade 3-4) | 0.86 [0.44, 1.69] | | < 1 | | 94% | 4 studies (4/-) | 66.8 % | low | not evaluable | high | non important | - |
TRAE leading to death (grade 5) | 1.09 [0.47, 2.52] | | < 1 | | 0% | 3 studies (3/-) | 42.2 % | some concern | not evaluable | moderate | non important | - |
TRAE leading to discontinuation (any grade) | 1.05 [0.42, 2.63] | | < 1 | | 0% | 1 study (1/-) | 45.7 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
Abdominal pain TRAE (grade 3-4) | 0.94 [0.06, 15.18] | | < 1 | | 0% | 1 study (1/-) | 51.6 % | NA | not evaluable | | non important | - |
Acute kidney injury TRAE (grade 3-4) | 0.47 [0.02, 14.11] | | < 1 | | 0% | 1 study (1/-) | 66.5 % | NA | not evaluable | | non important | - |
Adrenal insufficiency TRAE (grade 3-4) | 1.45 [0.11, 18.96] | | < 1 | | 0% | 2 studies (2/-) | 38.9 % | some concern | not evaluable | moderate | non important | - |
Alopecia TRAE (grade 3-4) | 0.84 [0.22, 3.26] | | < 1 | | 0% | 2 studies (2/-) | 59.7 % | low | not evaluable | high | non important | - |
Anaemia TRAE (grade 3-4) | 0.65 [0.17, 2.54] | | < 1 | | 76% | 2 studies (2/-) | 73.3 % | low | not evaluable | high | non important | - |
Asthenia TRAE (grade 3-4) | 1.26 [0.28, 5.69] | | < 1 | | 0% | 1 study (1/-) | 38.1 % | NA | not evaluable | | non important | - |
Colitis TRAE (grade 3-4) | 1.28 [0.19, 8.58] | | < 1 | | 0% | 3 studies (3/-) | 39.9 % | low | not evaluable | high | non important | - |
Constipation TRAE (grade 3-4) | 0.47 [0.02, 14.11] | | < 1 | | 0% | 1 study (1/-) | 66.5 % | NA | not evaluable | | non important | - |
Cough TRAE (grade 3-4) | 1.89 [0.06, 56.64] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
Decreased appetite TRAE (grade 3-4) | 0.47 [0.02, 14.11] | | < 1 | | 0% | 1 study (1/-) | 66.5 % | NA | not evaluable | | non important | - |
Diabetes TRAE (grade 3-4) | 0.97 [0.10, 9.35] | | < 1 | | 0% | 2 studies (2/-) | 51.1 % | some concern | not evaluable | moderate | non important | - |
Diarrhoea TRAE (grade 3-4) | 0.23 [0.05, 1.10] | | < 1 | | 0% | 1 study (1/-) | 96.7 % | NA | not evaluable | | non important | - |
Dyspnoea TRAE (grade 3-4) | 1.89 [0.06, 56.64] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
Fatigue TRAE (grade 3-4) | 1.10 [0.50, 2.40] | | < 1 | | 0% | 2 studies (2/-) | 41.0 % | low | not evaluable | high | non important | - |
Febrile neutropenia TRAE (grade 3-4) | 0.05 [0.00, 0.79] | | < 1 | | 0% | 1 study (1/-) | 98.2 % | NA | not evaluable | | non important | - |
Guillain-Barré syndrome TRAE (grade 3-4) | 0.51 [0.02, 15.24] | | < 1 | | 0% | 1 study (1/-) | 65.0 % | NA | not evaluable | | non important | - |
Headache TRAE (grade 3-4) | 1.89 [0.06, 56.64] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
Hepatitis TRAE (grade 3-4) | 1.02 [0.02, 51.63] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
Hyperthyroidism TRAE (grade 3-4) | 0.99 [0.12, 8.48] | | < 1 | | 0% | 3 studies (3/-) | 50.4 % | low | not evaluable | high | non important | - |
Hypothyroidism TRAE (grade 3-4) | 1.65 [0.23, 11.97] | | < 1 | | 0% | 3 studies (3/-) | 31.0 % | low | not evaluable | high | non important | - |
Increase AST TRAE (grade 3-4) | 1.91 [0.57, 6.42] | | < 1 | | 0% | 1 study (1/-) | 14.7 % | NA | not evaluable | | non important | - |
Increased ALT TRAE (grade 3-4) | 1.32 [0.70, 2.49] | | < 1 | | 0% | 2 studies (2/-) | 19.5 % | low | not evaluable | high | non important | - |
Infusion-related reactions TRAE (grade 3-4) | 1.02 [0.06, 16.42] | | < 1 | | 0% | 1 study (1/-) | 49.5 % | NA | not evaluable | | non important | - |
Leucopenia TRAE (grade 3-4) | 0.46 [0.07, 3.09] | | < 1 | | 53% | 2 studies (2/-) | 78.8 % | low | not evaluable | high | non important | - |
Maculopapular rash TRAE (grade 3-4) | 1.89 [0.06, 56.64] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
Myalgia TRAE (grade 3-4) | 0.47 [0.02, 14.11] | | < 1 | | 0% | 1 study (1/-) | 66.5 % | NA | not evaluable | | non important | - |
Myositis TRAE (grade 3-4) | 3.65 [0.38, 34.56] | | < 1 | | 0% | 2 studies (2/-) | 13.1 % | some concern | not evaluable | moderate | non important | - |
Nausea TRAE (grade 3-4) | 1.03 [0.33, 3.14] | | < 1 | | 0% | 2 studies (2/-) | 48.3 % | low | not evaluable | high | non important | - |
Nephritis TRAE (grade 3-4) | 0.94 [0.02, 47.78] | | < 1 | | 0% | 1 study (1/-) | 51.1 % | NA | not evaluable | | non important | - |
Neutropenia TRAE (grade 3-4) | 0.11 [0.00, 12.49] | | < 1 | | 91% | 2 studies (2/-) | 81.5 % | low | not evaluable | high | non important | - |
Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) | 0.13 [0.02, 1.08] | | < 1 | | 0% | 1 study (1/-) | 97.0 % | NA | not evaluable | | non important | - |
Pancytopenia TRAE (grade 3-4) | 0.24 [0.01, 5.23] | | < 1 | | 0% | 1 study (1/-) | 81.7 % | NA | not evaluable | | non important | - |
Peripheral sensory neuropathy TRAE (grade 3-4) | 0.16 [0.01, 3.13] | | < 1 | | 0% | 1 study (1/-) | 88.5 % | NA | not evaluable | | non important | - |
Pneumonia TRAE (grade 3-4) | 0.24 [0.01, 5.23] | | < 1 | | 0% | 1 study (1/-) | 81.7 % | NA | not evaluable | | non important | - |
Pneumonitis TRAE (grade 3-4) | 4.41 [0.75, 26.04] | | < 1 | | 0% | 3 studies (3/-) | 5.1 % | low | not evaluable | high | non important | - |
Pruritus TRAE (grade 3-4) | 1.89 [0.06, 56.64] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
Pyrexia TRAE (grade 3-4) | 0.94 [0.06, 15.18] | | < 1 | | 0% | 1 study (1/-) | 51.6 % | NA | not evaluable | | non important | - |
Rash TRAE (grade 3-4) | 1.02 [0.32, 3.23] | | < 1 | | 0% | 1 study (1/-) | 48.7 % | NA | not evaluable | | non important | - |
Sepsis TRAE (grade 3-4) | 0.94 [0.02, 47.78] | | < 1 | | 0% | 1 study (1/-) | 51.1 % | NA | not evaluable | | non important | - |
Severe skin reaction TRAE (grade 3-4) | 3.01 [0.57, 15.90] | | < 1 | | 0% | 3 studies (3/-) | 9.8 % | low | not evaluable | high | non important | - |
Stomatitis TRAE (grade 3-4) | 0.47 [0.02, 14.11] | | < 1 | | 0% | 1 study (1/-) | 66.5 % | NA | not evaluable | | non important | - |
Thrombocytopenia TRAE (grade 3-4) | 0.94 [0.06, 15.18] | | < 1 | | 0% | 1 study (1/-) | 51.6 % | NA | not evaluable | | non important | - |
Thyroiditis TRAE (grade 3-4) | 0.94 [0.02, 47.78] | | < 1 | | 0% | 1 study (1/-) | 51.1 % | NA | not evaluable | | non important | - |
Urticaria TRAE (grade 3-4) | 1.89 [0.06, 56.64] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
Weight decreased TRAE (grade 3-4) | 0.47 [0.04, 5.22] | | < 1 | | 0% | 1 study (1/-) | 72.9 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
hepatitis (Autoimmune) AE (grade 3-4) | 0.96 [0.06, 15.47] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
Abdominal pain AE (grade 3-4) | 1.24 [0.17, 8.82] | | < 1 | | 0% | 2 studies (2/-) | 41.6 % | low | not evaluable | high | non important | - |
Acute kidney injury AE (grade 3-4) | 1.93 [0.06, 57.72] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
Adrenal insufficiency AE (grade 3-4) | 1.93 [0.06, 57.72] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
Alopecia AE (grade 3-4) | 1.62 [0.21, 12.61] | | < 1 | | 0% | 2 studies (2/-) | 32.3 % | low | not evaluable | high | non important | - |
Anaemia AE (grade 3-4) | 1.12 [0.64, 1.94] | | < 1 | | 0% | 2 studies (2/-) | 34.9 % | low | not evaluable | high | non important | - |
Arthralgia AE (grade 3-4) | 0.98 [0.10, 9.47] | | < 1 | | 0% | 2 studies (2/-) | 50.6 % | low | not evaluable | high | non important | - |
Asthenia AE (grade 3-4) | 0.98 [0.31, 3.12] | | < 1 | | 0% | 2 studies (2/-) | 51.1 % | low | not evaluable | high | non important | - |
Back pain AE (grade 3-4) | 2.51 [0.57, 11.10] | | < 1 | | 0% | 2 studies (2/-) | 11.3 % | low | not evaluable | high | non important | - |
Cardiomyopathy AE (grade 3-4) | 1.93 [0.06, 57.72] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
Chills AE (grade 3-4) | 1.93 [0.06, 57.72] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
Colitis AE (grade 3-4) | 0.96 [0.06, 15.47] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
Constipation AE (grade 3-4) | 1.70 [0.26, 11.21] | | < 1 | | 0% | 2 studies (2/-) | 29.2 % | low | not evaluable | high | non important | - |
Cough AE (grade 3-4) | 0.99 [0.06, 15.89] | | < 1 | | 0% | 2 studies (2/-) | 50.2 % | low | not evaluable | high | non important | - |
Decreased appetite AE (grade 3-4) | 0.97 [0.22, 4.30] | | < 1 | | 0% | 2 studies (2/-) | 51.5 % | low | not evaluable | high | non important | - |
Diarrhoea AE (grade 3-4) | 1.36 [0.33, 5.60] | | < 1 | | 40% | 2 studies (2/-) | 33.4 % | low | not evaluable | high | non important | - |
Dizziness AE (grade 3-4) | 0.96 [0.02, 48.73] | | < 1 | | 0% | 1 study (1/-) | 50.7 % | NA | not evaluable | | non important | - |
Dry skin AE (grade 3-4) | 2.04 [0.07, 61.32] | | < 1 | | 0% | 1 study (1/-) | 34.3 % | NA | not evaluable | | non important | - |
Dysgeusia AE (grade 3-4) | 0.99 [0.06, 15.89] | | < 1 | | 0% | 2 studies (2/-) | 50.2 % | low | not evaluable | high | non important | - |
Dyspepsia AE (grade 3-4) | 1.02 [0.02, 51.63] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
Dysphonia AE (grade 3-4) | 1.93 [0.06, 57.72] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
Dyspnoea AE (grade 3-4) | 0.99 [0.28, 3.42] | | < 1 | | 0% | 2 studies (2/-) | 50.9 % | low | not evaluable | high | non important | - |
Epistaxis AE (grade 3-4) | 1.02 [0.02, 51.63] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
Fatigue AE (grade 3-4) | 1.13 [0.61, 2.08] | | < 1 | | 0% | 2 studies (2/-) | 34.8 % | low | not evaluable | high | non important | - |
Febrile neutropenia AE (grade 3-4) | 1.25 [0.61, 2.57] | | < 1 | | 0% | 1 study (1/-) | 27.3 % | NA | not evaluable | | non important | - |
Headache AE (grade 3-4) | 0.49 [0.11, 2.23] | | < 1 | | 0% | 2 studies (2/-) | 82.3 % | low | not evaluable | high | non important | - |
Hypertension AE (grade 3-4) | 0.59 [0.25, 1.38] | | < 1 | | 31% | 2 studies (2/-) | 89.0 % | low | not evaluable | high | non important | - |
Hyperthyroidism AE (grade 3-4) | 1.93 [0.06, 57.72] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
Hypothyroidism AE (grade 3-4) | 0.96 [0.02, 48.73] | | < 1 | | 0% | 1 study (1/-) | 50.7 % | NA | not evaluable | | non important | - |
Increase AST AE (grade 3-4) | 1.33 [0.56, 3.16] | | < 1 | | 17% | 2 studies (2/-) | 25.9 % | low | not evaluable | high | non important | - |
Increased ALT AE (grade 3-4) | 1.13 [0.55, 2.31] | | < 1 | | 0% | 2 studies (2/-) | 36.8 % | low | not evaluable | high | non important | - |
Infusion-related reaction AE (grade 3-4) | 1.02 [0.06, 16.42] | | < 1 | | 0% | 1 study (1/-) | 49.5 % | NA | not evaluable | | non important | - |
Lacrimation increased AE (grade 3-4) | 1.02 [0.02, 51.63] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
Leucopenia AE (grade 3-4) | 1.73 [0.86, 3.49] | | < 1 | | 0% | 2 studies (2/-) | 6.3 % | low | not evaluable | high | non important | - |
Mucosal inflammation AE (grade 3-4) | 1.96 [0.43, 8.98] | | < 1 | | 0% | 2 studies (2/-) | 19.4 % | low | not evaluable | high | non important | - |
Myalgia AE (grade 3-4) | 0.83 [0.17, 4.04] | | < 1 | | 0% | 2 studies (2/-) | 59.3 % | low | not evaluable | high | non important | - |
Myopathy AE (grade 3-4) | 1.93 [0.06, 57.72] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |